95 results on '"de Jesus, G."'
Search Results
2. A LIBRAS COMO INSTRUMENTO DE INCLUSÃO E ACESSO À CULTURA POPULAR E AO ENTRETENIMENTO DE PESSOAS SURDAS
- Author
-
Ferreira, Clayton Gabriel Pavão, primary, Ferreira, Heridan de Jesus G., additional, and Chahini, Thelma Helena, additional
- Published
- 2022
- Full Text
- View/download PDF
3. QUALIDADE FÍSICO-QUÍMICA DO LEITE CRU REFRIGERADO FORNECIDO A AGROINDÚSTRIA SOB SERVIÇO DE INSPEÇÃO ESTADUAL NO ESTADO DO MARANHÃO
- Author
-
SOUSA, A. K. A, primary, COSTA, D. de S., additional, SERRA, S. R. P., additional, DE JESUS, G. dos S., additional, GUIMARÃES, B. R. R., additional, FALCÃO, M. de A., additional, Santos, H. P., additional, Coimbra, V. C. S, additional, BEZERRA, D. C., additional, and Bezerra, N. P. C., additional
- Published
- 2022
- Full Text
- View/download PDF
4. Assessment of the effective viscous dissipation for deagglomeration processes induced by a high shear impeller in a stirred tank
- Author
-
Ramírez-Muñoz, J., Martínez-de-Jesús, G., Soria, A., Alonso, A., and Torres, L.G.
- Published
- 2016
- Full Text
- View/download PDF
5. Reflexões em Torno da Educação para a Igualdade de Género nas Primeiras Idades
- Author
-
Marchão, Amélia De Jesus G.
- Subjects
Gender equality ,Pre-school education ,Children's opinions ,Cidadania ,Igualdade de Género ,Opiniões das Crianças ,Estereótipos ,Citizenship ,Stereotypes ,Educação Pré-escolar - Abstract
Com este artigo visamos contribuir para uma reflexão mais aprofundada sobre a educação na e para a cidadania na educação pré-escolar e, de modo particular, refletir sobre a necessidade da educação para a igualdade de género neste contexto educativo. Neste sentido apresentamos uma pequena revisão do estado da arte e conjugamo-la com resultados de um pequeno estudo realizado num jardim de infância de um concelho do Alto Alentejo, onde, através da escuta das crianças, por via de uma entrevista, se apuraram as suas opiniões sobre o género e os papéis de género. Do cruzamento entre o estado da arte e as opiniões das crianças salienta-se o facto de esta questão necessitar de uma maior valorização e intencionalidade educativa no jardim de infância, de forma a contribuir para a construção de uma identidade de género livre de estereótipos., Interacções, Vol. 18 N.º 61 (2022): Género, Educação para a Cidadania e Infâncias
- Published
- 2022
6. A avaliação da aprendizagem na educação pré-escolar. O portefólio da criança
- Author
-
Amélia de Jesus G. Marchão and Ana Cristina Presumido Fitas
- Subjects
Educación pre-escolar, currículo, evaluación, portafolio. ,Education (General) ,L7-991 - Abstract
Este estudo leva-nos a reconhecer a importância da avaliação no contexto da educação pré-escolar e a encará-la num sentido contextual e sistémico. Quando se considera a criança como um ‘ser competente’, torna-se necessário aceitar a sua participação e capacidade de decidir, nomeadamente quando se trata de avaliar o seu percurso e as suas aprendizagens. Nesse sentido, o/ educador/a de infância deve promover práticas alternativas de avaliação das aprendizagens das crianças, surgindo o portefólio como um instrumento que promove a comunicação, a curiosidade, a partilha e a utilização do pensamento para atribuir significados. O portefólio apresenta-se como um instrumento de avaliação inovador e a sua construção é amplamente participada e valorizada pelas crianças e também pelas famílias, assumindo o educador um papel de orientador do processo construtivo e formativo em que a criança é a protagonista.
- Published
- 2014
7. Assessment of Reversibility for Covalent Cysteine Protease Inhibitors Using Quantum Mechanics/Molecular Mechanics Free Energy Surfaces
- Author
-
Dos Santos, Alberto M., primary, Oliveira, Amanda Ruslana Santana, additional, da Costa, Clauber H. S., additional, Kenny, Peter W., additional, Montanari, Carlos A., additional, Varela, Jaldyr de Jesus G., additional, and Lameira, Jerônimo, additional
- Published
- 2022
- Full Text
- View/download PDF
8. A LIBRAS COMO INSTRUMENTO DE INCLUSÃO E ACESSO À CULTURA POPULAR E AO ENTRETENIMENTO DE PESSOAS SURDAS
- Author
-
Clayton Gabriel Pavão Ferreira, Heridan de Jesus G. Ferreira, and Thelma Helena Chahini
- Published
- 2022
9. Assessment of Reversibility for Covalent Cysteine Protease Inhibitors Using Quantum Mechanics/Molecular Mechanics Free Energy Surfaces
- Author
-
Alberto M. Dos Santos, Amanda Ruslana Santana Oliveira, Clauber H. S. da Costa, Peter W. Kenny, Carlos A. Montanari, Jaldyr de Jesus G. Varela, and Jerônimo Lameira
- Subjects
General Chemical Engineering ,Cathepsin K ,Quantum Theory ,Protease Inhibitors ,General Chemistry ,Cysteine Proteinase Inhibitors ,Molecular Dynamics Simulation ,Library and Information Sciences ,ENERGIA ,Catalysis ,Computer Science Applications - Abstract
We have used molecular dynamics (MD) simulations with hybrid quantum mechanics/molecular mechanics (QM/MM) potentials to investigate the reaction mechanism for covalent inhibition of cathepsin K and assess the reversibility of inhibition. The computed free energy profiles suggest that a nucleophilic attack by the catalytic cysteine on the inhibitor warhead and proton transfer from the catalytic histidine occur in a concerted manner. The results indicate that the reaction is more strongly exergonic for the alkyne-based inhibitors, which bind irreversibly to cathepsin K, than for the nitrile-based inhibitor odanacatib, which binds reversibly. Gas-phase energies were also calculated for the addition of methanethiol to structural prototypes for a number of warheads of interest in cysteine protease inhibitor design in order to assess electrophilicity. The approaches presented in this study are particularly applicable to assessment of novel warheads, and computed transition state geometries can be incorporated into molecular models for covalent docking.
- Published
- 2022
10. Caesarean rates in Brazil: what is involved?
- Author
-
Ramires de Jesus, G, Ramires de Jesus, N, Peixoto-Filho, F M, and Lobato, G
- Published
- 2015
- Full Text
- View/download PDF
11. Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria
- Author
-
Barbhaiya, M., Zuily, S., Ahmadzadeh, Y., Amigo, M. -C., Avcin, T., Bertolaccini, M., Branch, D. W., de Jesus, G., Devreese, K. M. J., Frances, C., Garcia, D., Guillemin, F., Levine, S. R., Levy, R. A., Lockshin, M. D., Ortel, T., Seshan, S. V., Tektonidou, M., Wahl, D., Willis, R., Naden, R., Costenbader, K., Erkan, D., Agmon-Levin, N., Aguilar, C., Alba, P., Alpan, O., Ambrozic, A., Amoura, Z., Andrade, D., Andrade, L., Appenzeller, S., Esen, B. A., Atsumi, T., Berkun, Y., Cabral, A., Canaud, G., Cervera, R., Chen, P., Chighizola, C., Cimaz, R., Cohen, H., Costedoat-Chalumeau, N., Crowther, M., Cuadrado, M. J., de Groot, P. G., de Moerloose, P., Derksen, R., Diz-Kucukkaya, R., Dorner, T., Fortin, P., Giannakopoulos, B., Gomez-Puerta, J. A., Gonzalez, E. B., Inanc, M., Kenet, G., Khamashta, M., Kriegel, M., Krilis, S., Laskin, C., Massicotte, P., Mccarty, G., Meroni, P. L., Mikdashi, J., Myones, B., Pengo, V., Petri, M., Roubey, R., Sammaritano, L., Sanna, G., Sciascia, S., Signorelli, F., Soybilgic, A., Tincani, A., Woller, S., and Yelnik, C.
- Subjects
Antiphospholipid Syndrome ,Consensus ,Delphi Technique ,Humans ,Predictive Value of Tests ,Rheumatology ,Severity of Illness Index ,CONSENSUS STATEMENT ,Potential candidate ,AMERICAN-COLLEGE ,Article ,DISEASE ,Reduction (complexity) ,03 medical and health sciences ,0302 clinical medicine ,Antiphospholipid syndrome ,RHEUMATOLOGY/EUROPEAN LEAGUE ,Nominal group technique ,Medicine and Health Sciences ,Hierarchical organization ,Medicine ,CLINICAL-SIGNIFICANCE ,computer.programming_language ,030203 arthritis & rheumatology ,RISK ,VENOUS THROMBOEMBOLISM ,Information retrieval ,business.industry ,SYSTEMIC-SCLEROSIS ,medicine.disease ,Phase i ii ,MYOCARDIAL-INFARCTION ,ANTIBODIES ,Report generation ,business ,computer ,Delphi - Abstract
Objective : An international multidisciplinary initiative, jointly supported by the American College of Rheumatology and European Alliance of Associations for Rheumatology, is underway to develop new rigorous classification criteria to identify patients with high likelihood of antiphospholipid syndrome (APS) for research purposes. The present study was undertaken to apply an evidence- and consensus-based approach to identify candidate criteria and develop a hierarchical organization of criteria within domains. Methods : During phase I, the APS classification criteria steering committee used systematic literature reviews and surveys of international APS physician scientists to generate a comprehensive list of items related to APS. In phase II, we reviewed the literature, administered surveys, formed domain subcommittees, and used Delphi exercises and nominal group technique to reduce potential APS candidate criteria. Candidate criteria were hierarchically organized into clinical and laboratory domains. Results : Phase I generated 152 candidate criteria, expanded to 261 items with the addition of subgroups and candidate criteria with potential negative weights. Using iterative item reduction techniques in phase II, we initially reduced these items to 64 potential candidate criteria organized into 10 clinical and laboratory domains. Subsequent item reduction methods resulted in 27 candidate criteria, hierarchically organized into 6 additive domains (laboratory, macrovascular, microvascular, obstetric, cardiac, and hematologic) for APS classification. Conclusion : Using data- and consensus-driven methodology, we identified 27 APS candidate criteria in 6 clinical or laboratory domains. In the next phase, the proposed candidate criteria will be used for real-world case collection and further refined, organized, and weighted to determine an aggregate score and threshold for APS classification.
- Published
- 2021
12. A trajetória da ABEn - Alagoas
- Author
-
Lenira M. ª W. S. de Almeida, M.ª Lysete de Assis Bastos, Teresinha de Jesus G. Costa, and Vera Grácia N. Monteiro
- Subjects
ABEn-AL ,enfermería alagoana ,organización de la enfermería ,Nursing ,RT1-120 - Abstract
Este artigo traça a trajetória da ABEn-AL e a sua influência na organização da enfermagem no estado, já que foi fundada muito antes de haver curso de graduação em enfermagem em Alagoas e antes da existência de qualquer outra entidade de classe, constituindo-se assim um marco decisivo tanto na organização como no desencadeamento das lutas da categoria no Estado de Alagoas.
- Published
- 2001
- Full Text
- View/download PDF
13. INCESSANT FOCAL ATRIAL TACHYCARDIA DURING PREGNANCY AND POSTPARTUM PERIOD
- Author
-
Benitez, Jose Ramon, primary, Garcia, Gabriela Andrea Bustillos, additional, Mendoza, Juan Alan Fuentes, additional, Ureña, Elizabeth Gomez, additional, Ruiz, Pedro Arredondo, additional, Laura De Jesus, G., additional, and Luna, Enrique Alessio Garibo, additional
- Published
- 2020
- Full Text
- View/download PDF
14. Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy
- Author
-
Giannakopoulos, B, Krilis, S, de Jesus, G, Levy, R, Rosa, R, Andrade, D, Fortin, Pf, Zhang, Z, Zuily, S, Wahl, D, Tektonidou, M, Nalli, C, Andreoli, L, Tincani, A, Chighizola, Cb, Gerosa, M, Meroni, P, Banzato, A, Pengo, V, Sciascia, S, De Ceulaer, K, Davis, S, Atsumi, T, Uthman, I, Derksen, R, Degroot, P, Ugarte, A, Ruiz Irastorza, G, Rodriguez-Pinto, I, Pons-Estel, G, Cervera, R, Rodriguez, E, Aguirre Zamorano MA, Lopez-Pedrera), R, Mackie, I, Efthymiou, M, Cohen, H, Bertolaccini, Ml, Cuadrado, M, Khamashta, M, Sanna, G, Petri, M, Roubey, R, Knight, Js, Ortel, T, Gonzalez, E, Willis, Jhon Raymond, Levine, S, Rand, J, Belmont, Hm, Barbhaiya, M, Erkan, D, Salmon, J, Lockshin, M, Branch, W, Jackson, Wg, Oromendia, C, Unlu, O, and Desancho, Mt
- Subjects
030203 arthritis & rheumatology ,medicine.medical_specialty ,biology ,medicine.drug_class ,business.industry ,Anticoagulant ,Hematology ,030204 cardiovascular system & hematology ,Single Center ,medicine.disease ,Thrombosis ,Thrombosis and Hemostasis ,Clinical trial ,03 medical and health sciences ,0302 clinical medicine ,Antiphospholipid syndrome ,Internal medicine ,Antithrombotic ,medicine ,biology.protein ,In patient ,Antibody ,business - Abstract
Management for patients with antiphospholipid syndrome (APS) and arterial thrombosis is controversial. There are no prospective data demonstrating the superiority of high- or moderate-intensity anticoagulation with vitamin K antagonists over antiplatelet agents. Using 2 antiphospholipid antibody databases (single center [New York Presbyterian Hospital] and multicenter [Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking]), we retrospectively collected demographic and clinical data of patients with APS and arterial thrombosis. The primary outcome was recurrent thrombosis rate after initial arterial thrombosis in patients with APS treated with antiplatelet and/or anticoagulant therapy. We identified 139 patients with a median follow-up time of 4.24 years after initial thrombosis. Thirty-seven patients (27.3%) received anticoagulants, 43 (30.9%) antiplatelets, and 58 (41.7%) combined therapy. Sixteen patients (37.2%) in the antiplatelet group, 9 (23.7%) in the anticoagulant group, and 4 (6.9%) in the combined therapy group experienced recurrent thrombosis. We estimate that 20% of patients will experience a recurrence by 3.4, 7.3, and 16.3 years, respectively, depending on assignment to antiplatelet, anticoagulant, or combined therapy. These results suggest that combined therapy decreases the rate of and increases the time to thrombosis recurrence in patients with APS presenting with arterial thrombosis.
- Published
- 2017
15. Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository
- Author
-
Efthymiou, M. Mackie, I.J. Lane, P.J. Andrade, D. Willis, R. Erkan, D. Sciascia, S. Krillis, S. Bison, E. Borges Galhardo Vendramini, M. Romay-Penabad, Z. Qi, M. Tektonidou, M. Ugarte, A. Chighizola, C. Belmont, H.M. Aguirre, M.A. Ji, L. Branch, D.W. de Jesus, G. Fortin, P.R. Andreoli, L. Petri, M. Cervera, R. Rodriguez, E. Knight, J.S. Atsumi, T. Vega, J. Sevim, E. Bertolaccini, M.L. Pengo, V. Cohen, H. on behalf of APS ACTION
- Abstract
Background: Variability remains a challenge in lupus anticoagulant (LA) testing. Objective: To validate LA test performance between Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Core laboratories and examine agreement in LA status between Core and local/hospital laboratories contributing patients to this prospective registry. Methods: Five Core laboratories used the same reagents, analyzer type, protocols, and characterized samples for LA validation. Non-anticoagulated registry samples were retested at the corresponding regional Core laboratories and anticoagulated samples at a single Core laboratory. Categorical agreement and discrepancies in LA status between Core and local/hospital laboratories were analyzed. Results: Clotting times for the reference/characterized plasmas used for normalized ratios were similar between Core laboratories (CV
- Published
- 2019
16. Characterization of Mechanisms of Resistance in Previously Treated Chronic Lymphocytic Leukemia (CLL) From a Head‐to‐Head Trial of Acalabrutinib Versus Ibrutinib.
- Author
-
Woyach, J. A., Jones, D., Jurczak, W., Robak, T., Illés, A., Kater, A. P., Ghia, P., Byrd, J. C., Seymour, J. F., Long, S., Mohamed, N., De Jesus, G., Lai, R., de Bruin, G., Butturini, A., Rule, S., and Munugalavadla, V.
- Subjects
CHRONIC lymphocytic leukemia ,BRUTON tyrosine kinase - Abstract
In ELEVATE-RR (NCT02477696) at a median follow-up of 41 mo, Acala demonstrated noninferior progression-free survival with fewer cardiovascular adverse events versus ibrutinib (Ibr) in patients (pts) with relapsed/refractory (R/R) CLL. Characterization of Mechanisms of Resistance in Previously Treated Chronic Lymphocytic Leukemia (CLL) From a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib B Introduction: b Acalabrutinib (Acala) is a highly selective, next-generation covalent Bruton tyrosine kinase inhibitor (BTKi) approved for CLL. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
17. APS ACTION – AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking
- Author
-
Erkan, D, Lockshin, Md, Andreoli, Laura, Branch, W, Brey, R, Cervera, R, Cohen, H, Cuadrado, M, Degroot, P, Derksen, R, Fortin, P, Giannakopoulos, B, Harris, N, Khamashta, M, Krilis, S, Levine, Sr, Levy, R, Lockshin, M, Machin, S, Meroni, P, Ortel, T, Pengo, V, Pierangeli, S, Pons Estel, G, Rand, J, Roubey, R, Salmon, J, Tincani, Angela, Wahl, D, Banzato, A, Chighizola, Cb, and de Jesus, G.
- Subjects
medicine.medical_specialty ,education ,Alternative medicine ,Article ,law.invention ,Rheumatology ,Randomized controlled trial ,immune system diseases ,Antiphospholipid syndrome ,law ,medicine ,Humans ,Intensive care medicine ,Randomized Controlled Trials as Topic ,Systemic lupus erythematosus ,business.industry ,Hydroxychloroquine ,Antiphospholipid Syndrome ,medicine.disease ,Clinical trial ,Alliance ,Action (philosophy) ,Antirheumatic Agents ,Immunology ,business ,medicine.drug - Abstract
AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking (APS ACTION) is the first-ever international research network that has been created specifically to design and conduct well-designed, large-scale, multi-center clinical trials in persistently antiphospholipid antibody (aPL)-positive patients. The founding principle of the APS ACTION is that it is an internationally collaborative effort, open to qualified investigators across the globe who are committed to furthering our understanding of APS and its management. Due to the hard work and collaborative spirit of APS ACTION members, in early 2012, APS ACTION launched two important collaborative international projects: 1) a randomized controlled trial of hydroxychloroquine in the primary thrombosis prevention of persistently aPL-positive but thrombosis-free patients without other systemic autoimmune diseases; and 2) a web-based registry of aPL-positive patients with or without systemic autoimmune diseases, which will also include annual blood collection for aPL-testing and future basic science studies. In the end, we hope to find better treatments for antiphospholipid syndrome, which is a leading cause of thrombosis, pregnancy morbidity and other life-altering consequences, and to heighten awareness about this life-threatening, autoimmune condition. Lupus (2012) 21, 695–698.
- Published
- 2012
18. Gestational outcomes in patients with neuropsychiatric systemic lupus erythematosus
- Author
-
de Jesus, G R, primary, Rodrigues, B C, additional, Lacerda, M I, additional, dos Santos, F C, additional, de Jesus, NR, additional, Klumb, E M, additional, and Levy, R A, additional
- Published
- 2017
- Full Text
- View/download PDF
19. NEEDS-ASSESSMENT SURVEY FOR THE UPDATE OF THE CURRENT ANTIPHOSPHOLIPID SYNDROME (APS) CLASSIFICATION CRITERIA
- Author
-
Barbhaiya, M. Abreu, M. Amigo, M. C. Avcin, T. and Bertolaccini, M. L. Branch, W. de Groot, P. G. de Jesus, G. and Levy, R. Lockshin, M. Tektonidou, M. Wahl, D. and Willis, R. Zuily, S. Costenbader, K. Erkan, D.
- Published
- 2015
20. La evaluación de aprendizajes en la educación pre-escolar. El portafolio de los niños
- Author
-
Amélia de Jesus G. Marchão and Ana Cristina Presumido Fitas
- Abstract
This study leads us to recognize the importance of evaluation in preschool education and to envisage it in a systematic and contextual sense.When we consider the child as a ‘competent person’ becomes necessary to accept their participation and ability to decide, especially when it concerns to evaluation of their journey and their learning. In this sense, the preschool teacher should promote alternative practices of evaluation for the child’s apprenticeship. The portfolio appears as an instrument that promotes communication, curiosity, sharing and the use of thought to assign meanings.The portfolio presents itself as an innovative instrument of evaluation and its construction is widely participated and appreciated by the children and their families, whereas the educator assumes a role of guiding of the constructive and formative process in which the child is the protagonist. Este estudio busca el reconocimiento de la importancia de la evaluación en el contexto de la educación pre-escolar, y su comprensión en un sentido contextual y sistémico. Si se considera al niño como un «ser competente» se hace necesario aceptar su participación y su capacidad de decidir, especialmente cuando se trata de evaluar su recorrido académico y sus aprendizajes. En este sentido, el educador/ora de la infancia debe promover prácticas alternativas de evaluación del aprendizaje infantil. El portafolio surge como un instrumento que promueve la comunicación, la curiosidad, el acto de compartir y la utilización del pensamiento para atribuir significados. Así, el portafolio aparece como un instrumento de evaluación innovador, construido con la amplia participación y valoración de los niños, y también de las familias. El educador asume el papel de orientador del proceso constructivo e informativo, durante el cuál el niño es el protagonista. Este estudo leva-nos a reconhecer a importância da avaliação no contexto da educação pré-escolar e a encará-la num sentido contextual e sistémico. Quando se considera a criança como um ‘ser competente’, torna-se necessário aceitar a sua participação e capacidade de decidir, nomeadamente quando se trata de avaliar o seu percurso e as suas aprendizagens. Nesse sentido, o/ educador/a de infância deve promover práticas alternativas de avaliação das aprendizagens das crianças, surgindo o portefólio como um instrumento que promove a comunicação, a curiosidade, a partilha e a utilização do pensamento para atribuir significados. O portefólio apresenta-se como um instrumento de avaliação inovador e a sua construção é amplamente participada e valorizada pelas crianças e também pelas famílias, assumindo o educador um papel de orientador do processo construtivo e formativo em que a criança é a protagonista.
- Published
- 2014
21. Caesarean Rates in Brazil
- Author
-
de Jesus, G. Ramires, primary, de Jesus, N. Ramires, additional, Peixoto-Filho, F.M., additional, and Lobato, G., additional
- Published
- 2016
- Full Text
- View/download PDF
22. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature
- Author
-
Andreoli, Laura, Chighizola, Cb, Banzato, A, Pons Estel GJ, Ramire de Jesus, G, and Erkan, D.
- Published
- 2013
23. AB0561 Needs-Assessment Survey for the Update of the Current Antiphospholipid Syndrome (APS) Classification Criteria
- Author
-
Barbhaiya, M., primary, Abreu, M., additional, Amigo, M.C., additional, Avcin, T., additional, Bertolaccini, M.L., additional, Branch, W., additional, de Groot, P.G., additional, de Jesus, G., additional, Levy, R., additional, Lockshin, M., additional, Tektonidou, M., additional, Wahl, D., additional, Willis, R., additional, Zuily, S., additional, Costenbader, K., additional, and Erkan, D., additional
- Published
- 2015
- Full Text
- View/download PDF
24. The association between antiphospholipid antibodies and pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature
- Author
-
Chighizola, C B, primary, Andreoli, L, additional, de Jesus, G Ramires, additional, Banzato, A, additional, Pons-Estel, G J, additional, and Erkan, D, additional
- Published
- 2015
- Full Text
- View/download PDF
25. Caesarean rates in Brazil: what is involved?
- Author
-
Ramires de Jesus, G, primary, Ramires de Jesus, N, additional, Peixoto-Filho, FM, additional, and Lobato, G, additional
- Published
- 2014
- Full Text
- View/download PDF
26. Prevalence and antimicrobial resistances of pathogens isolated on urine cultures on an internal medicine ward
- Author
-
Nobre de Jesus, G., primary, Gaspar da Costa, P., additional, Lêdo, L., additional, Meneses Santos, J., additional, Carvalho, D., additional, Lito, L.M., additional, Victorino, R.M.M., additional, and Melo Cristino, J., additional
- Published
- 2013
- Full Text
- View/download PDF
27. Microbial isolates in blood cultures in an internal medicine department
- Author
-
Trindade Nave, J., primary, Nobre de Jesus, G., additional, Santos Pinheiro, L., additional, Meneses Santos, J., additional, Lucas, M., additional, and Victorino, R.M.M., additional
- Published
- 2013
- Full Text
- View/download PDF
28. SAGE-B: a dynamic dam-break flood emergency management system
- Author
-
de Jesus, G., primary, Santos, M. A., additional, and Palha-Fernandes, J., additional
- Published
- 2010
- Full Text
- View/download PDF
29. A trajetória da ABEn - Alagoas
- Author
-
Almeida, Lenira M. ª W. S. de, primary, Bastos, M.ª Lysete de Assis, additional, Costa, Teresinha de Jesus G., additional, and Monteiro, Vera Grácia N., additional
- Published
- 2001
- Full Text
- View/download PDF
30. Panic disorder is unlikely to be a homogeneous autosomal dominant disorder: Results of a genome-wide genetic screen
- Author
-
Knowles, J.A., primary, Vieland, V.J., additional, Weissman, M.M., additional, Heiman, G., additional, de Jesus, G., additional, Judenberg, A., additional, Cunjak, J., additional, Mick, S., additional, Adams, P., additional, Hodge, S.E., additional, Klein, D.F., additional, Fyer, A.J., additional, and Gilliam, T.C., additional
- Published
- 1996
- Full Text
- View/download PDF
31. How do patients like to be addressed by hospital staff?
- Author
-
Marshall Ja, De Jesus G, E. G. Stewart-Wynne, and Tey Ly
- Subjects
medicine.medical_specialty ,business.industry ,Professional-Patient Relations ,General Medicine ,Personnel, Hospital ,Patient satisfaction ,Patient Satisfaction ,Surveys and Questionnaires ,Family medicine ,Humans ,Names ,Medicine ,business ,Personnel hospital - Published
- 1997
32. DISCUSSION. LINEAR ANALYSIS OF COMPLETE STRUCTURES BY COMPUTERS.
- Author
-
MEDLAND, I C, BELLAMY, J B, WILLIAMSON, M, MAJID, KI, COPE, R J, SAWKO, F, KHAN, M A, KHANNA, J, VAO, C C, DE JESUS, G C, and JENKINS, W H
- Published
- 1968
- Full Text
- View/download PDF
33. A reappraisal of the role of public enterprises in less developed countries: A comment.
- Author
-
Dollery, B E and de Jesus, G A
- Published
- 1986
- Full Text
- View/download PDF
34. DISCUSSION. LINEAR ANALYSIS OF COMPLETE STRUCTURES BY COMPUTERS
- Author
-
MAJID, KI, primary, WILLIAMSON, M, additional, SAWKO, F, additional, COPE, R J, additional, JENKINS, W H, additional, DE JESUS, G C, additional, BELLAMY, J B, additional, MEDLAND, I C, additional, VAO, C C, additional, KHANNA, J, additional, and KHAN, M A, additional
- Published
- 1968
- Full Text
- View/download PDF
35. An Extensible Co-browsing Environment with Conference Support.
- Author
-
Lima, C.V., Willrich, R., Gomes, R.L., de Jesus, G., Rivera, H., and Courtiat, J.-P.
- Published
- 2007
- Full Text
- View/download PDF
36. Microbial isolates in blood cultures in an internal medicine department.
- Author
-
Anonymous, Nobre de Jesus, G., Santos Pinheiro, L., Meneses Santos, J., Lucas, M., and Victorino, R.M.M.
- Published
- 2013
- Full Text
- View/download PDF
37. Care during conflicts: Emergency support systems in Oceania.
- Author
-
Tin D, Cheng L, Braitberg G, Naitini I, A de Jesus G, and Ciottone G
- Abstract
Objective: The present study analyses Oceania's protest and conflict events (2021-2022) to aid healthcare systems better understand the scope of the issue., Methods: Data from the Armed Conflict Location & Event Data database were examined for event types and fatalities., Results: A total of 2743 events were recorded, mainly protests (83.3%). Fatalities stemmed from battles, violence against civilians and riots. Australia had the most events (56.1%); Papua New Guinea the highest fatality rate (1.03/event)., Conclusions: Australia faced pandemic-related protests; Papua New Guinea grappled with tribal violence, posing healthcare challenges. A comprehensive approach emphasising disaster preparedness, regional cooperation and addressing root causes is crucial to bolster healthcare systems., (© 2024 Australasian College for Emergency Medicine.)
- Published
- 2024
- Full Text
- View/download PDF
38. ANA-positive versus ANA-negative Antiphospholipid Antibody-positive Patients: Results from the APS ACTION Clinical Database and Repository.
- Author
-
Cecchi I, Radin M, Foddai SG, Barinotti A, Andrade D, Tektonidou MG, Pengo V, Ruiz-Irastorza G, Belmont HM, Lopez Pedrera C, Fortin PR, Gerosa M, de Jesus G, Atsumi T, Ji L, Efthymiou M, Branch DW, Nalli C, Rodriguez-Almaraz E, Petri M, Cervera R, Knight J, Artim-Esen B, Willis R, Bertolaccini ML, Cohen H, Erkan D, and Sciascia S
- Abstract
Objectives: This study focused on the prevalence and impact of antinuclear antibodies (ANA) in antiphospholipid antibody (aPL)-positive patients without concomitant systemic autoimmune rheumatic diseases (SARDs)., Methods: Data from aPL-positive patients with or without Revised Sapporo APS classification criteria were retrieved from the APS ACTION Registry. Patients with concomitant SARDs were excluded., Results: 430 aPL-positive patients were included in the analysis, 56% ANA-positive and 44% negative. ANA positivity was significantly associated with history of hematologic manifestations (persistent autoimmune hemolytic anaemia, thrombocytopenia, leukopenia and/or lymphopenia) (16% of ANA-positive vs 7% of ANA-negative, p= 0.006). Triple aPL-positivity was more frequent in the ANA-positive subgroup (p= 0.02), along with low baseline C3 and C4 levels (p= 0.05 and p= 0.009, respectively), and higher frequency for extractable nuclear antigens (ENA). Among aPL-positive patients with no APS classification, ANA-positive patients showed a higher rate of arthritis (p= 0.006). Among female patients who have experienced at least one pregnancy, 113 were ANA-positive and 96 were ANA-negative; ANA-negative patients had a higher number of pregnancies (p= 0.018), and number of live births (p= 0.014). A wider proportion of ANA-positive patients were treated with hydroxychloroquine (HCQ) (p< 0.001)., Conclusion: When we analysed aPL-positive patients with no other SARDs, ANA status was not associated with thrombosis or pregnancy morbidity. Interestingly, ANA-positive patients showed higher rates of systemic autoimmune features, including hematologic manifestations, multiple aPL positivity, lower complement levels, ENA positivity, and joint involvement, and were more often treated with HCQ. Finally, aPL-positive subjects who were ANA-negative had a higher rate of pregnancies and live births., (© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
39. Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib.
- Author
-
Woyach JA, Jones D, Jurczak W, Robak T, Illés Á, Kater AP, Ghia P, Byrd JC, Seymour JF, Long S, Mohamed N, Benrashid S, Lai TH, De Jesus G, Lai R, de Bruin G, Rule S, and Munugalavadla V
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Disease Progression, Protein Kinase Inhibitors therapeutic use, Protein Kinase Inhibitors adverse effects, Protein Kinase Inhibitors administration & dosage, Adenine analogs & derivatives, Agammaglobulinaemia Tyrosine Kinase genetics, Agammaglobulinaemia Tyrosine Kinase antagonists & inhibitors, Benzamides therapeutic use, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Leukemia, Lymphocytic, Chronic, B-Cell genetics, Mutation, Piperidines therapeutic use, Pyrazines therapeutic use, Pyrazines administration & dosage, Pyrazoles therapeutic use, Pyrimidines therapeutic use, Pyrimidines administration & dosage
- Abstract
Abstract: Chronic lymphocytic leukemia (CLL) progression during Bruton tyrosine kinase (BTK) inhibitor treatment is typically characterized by emergent B-cell receptor pathway mutations. Using peripheral blood samples from patients with relapsed/refractory CLL in ELEVATE-RR (NCT02477696; median 2 prior therapies), we report clonal evolution data for patients progressing on acalabrutinib or ibrutinib (median follow-up, 41 months). Paired (baseline and progression) samples were available for 47 (excluding 1 Richter) acalabrutinib-treated and 30 (excluding 6 Richter) ibrutinib-treated patients. At progression, emergent BTK mutations were observed in 31 acalabrutinib-treated (66%) and 11 ibrutinib-treated patients (37%; median variant allele fraction [VAF], 16.1% vs 15.6%, respectively). BTK C481S mutations were most common in both groups; T474I (n = 9; 8 co-occurring with C481) and the novel E41V mutation within the pleckstrin homology domain of BTK (n = 1) occurred with acalabrutinib, whereas neither mutation occurred with ibrutinib. L528W and A428D comutations presented in 1 ibrutinib-treated patient. Preexisting TP53 mutations were present in 25 acalabrutinib-treated (53.2%) and 16 ibrutinib-treated patients (53.3%) at screening. Emergent TP53 mutations occurred with acalabrutinib and ibrutinib (13% vs 7%; median VAF, 6.0% vs 37.3%, respectively). Six acalabrutinib-treated patients and 1 ibrutinib-treated patient had emergent TP53/BTK comutations. Emergent PLCG2 mutations occurred in 3 acalabrutinib-treated (6%) and 6 ibrutinib-treated patients (20%). One acalabrutinib-treated patient and 4 ibrutinib-treated patients had emergent BTK/PLCG2 comutations. Although common BTK C481 mutations were observed with both treatments, patterns of mutation and comutation frequency, mutation VAF, and uncommon BTK variants varied with acalabrutinib (T474I and E41V) and ibrutinib (L528W and A428D) in this patient population. The trial was registered at www.clinicaltrials.gov as #NCT02477696., (© 2024 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
40. Anti-Leishmania activity and molecular docking of unusual flavonoids-rich fraction from Arrabidaea brachypoda (Bignoniaceae).
- Author
-
das Neves MA, do Nascimento JR, Maciel-Silva VL, Dos Santos AM, Junior JJGV, Coelho AJS, Lima MIS, Pereira SRF, and da Rocha CQ
- Subjects
- Animals, Mice, Inhibitory Concentration 50, Macrophages drug effects, Macrophages parasitology, RAW 264.7 Cells, Bignoniaceae chemistry, Antiprotozoal Agents pharmacology, Antiprotozoal Agents chemistry, Antiprotozoal Agents isolation & purification, Flavonoids pharmacology, Flavonoids chemistry, Molecular Docking Simulation, Leishmania drug effects, Leishmania genetics, Plant Extracts pharmacology, Plant Extracts chemistry, Plant Extracts isolation & purification
- Abstract
Leishmaniases comprise a group of infectious parasitic diseases caused by various species of Leishmania and are considered a significant public health problem worldwide. Only a few medications, including miltefosine, amphotericin B, and meglumine antimonate, are used in current therapy. These medications are associated with severe side effects, low efficacy, high cost, and the need for hospital support. Additionally, there have been occurrences of drug resistance. Additionally, only a limited number of drugs, such as meglumine antimonate, amphotericin B, and miltefosine, are available, all of which are associated with severe side effects. In this context, the need for new effective drugs with fewer adverse effects is evident. Therefore, this study investigated the anti-Leishmania activity of a dichloromethane fraction (DCMF) extracted from Arrabidaea brachypoda roots. This fraction inhibited the viability of L. infantum, L. braziliensis, and L. Mexicana promastigotes, with IC
50 values of 10.13, 11.44, and 11.16 µg/mL, respectively, and against L. infantum amastigotes (IC50 = 4.81 µg/mL). Moreover, the DCMF exhibited moderate cytotoxicity (CC50 = 25.15) towards RAW264.7 macrophages, with a selectivity index (SI) of 5.2. Notably, the DCMF caused damage to the macrophage genome only at 40 µg/mL, which is greater than the IC50 found for all Leishmania species. The results suggest that DCMF demonstrates similar antileishmanial effectiveness to isolated brachydin B, without causing genotoxic effects on mammalian cells. This finding is crucial because the isolation of the compounds relies on several steps and is very costly while obtaining the DCMF fraction is a simple and cost-effective process. Furthermore, In addition, the potential mechanisms of action of brachydins were also investigated. The computational analysis indicates that brachydin compounds bind to the Triosephosphate isomerase (TIM) enzyme via two main mechanisms: destabilizing the interface between the homodimers and interacting with catalytic residues situated at the site of binding. Based on all the results, DCMF exhibits promise as a therapeutic agent for leishmaniasis due to its significantly reduced toxicity in comparison to the adverse effects associated with current reference treatments., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
41. Development of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-D Report: Multicriteria Decision Analysis.
- Author
-
Barbhaiya M, Zuily S, Amigo MC, Andrade D, Avcin T, Bertolaccini ML, Branch DW, Costedoat-Chalumeau N, Crowther M, Ramires de Jesus G, Devreese KMJ, Frances C, Garcia D, Gómez-Puerta JA, Guillemin F, Levine SR, Levy RA, Lockshin MD, Ortel TL, Petri M, Sanna G, Sciascia S, Seshan SV, Tektonidou MG, Wahl D, Willis R, Yelnik C, Hendry A, Naden R, Costenbader K, and Erkan D
- Abstract
Objective: The 2023 American College of Rheumatology/EULAR antiphospholipid syndrome (APS) classification criteria development, which aimed to identify patients with high likelihood of APS for research, employed a four-phase methodology. Phase I and II resulted in 27 proposed candidate criteria, which are organized into laboratory and clinical domains. Here, we summarize the last stage of phase III efforts, employing a consensus-based multicriteria decision analysis (MCDA) to weigh candidate criteria and identify an APS classification threshold score., Methods: We evaluated 192 unique, international real-world patients referred for "suspected APS" with a wide range of APS manifestations. Using proposed candidate criteria, subcommittee members rank ordered 20 representative patients from highly unlikely to highly likely to have APS. During an in-person meeting, the subcommittee refined definitions and participated in an MCDA exercise to identify relative weights of candidate criteria. Using consensus decisions and pairwise criteria comparisons, 1000Minds software assigned criteria weights, and we rank ordered 192 patients by their additive scores. A consensus-based threshold score for APS classification was set., Results: Premeeting evaluation of 20 representative patients demonstrated variability in APS assessment. MCDA resolved 81 pairwise decisions; relative weights identified domain item hierarchy. After assessing 192 patients by weights and additive scores, the Steering Committee reached consensus that APS classification should require separate clinical and laboratory scores, rather than a single-aggregate score, to ensure high specificity., Conclusion: Using MCDA, candidate criteria preliminary weights were determined. Unlike other disease classification systems using a single-aggregate threshold score, separate clinical and laboratory domain thresholds were incorporated into the new APS classification criteria., (© 2024 American College of Rheumatology.)
- Published
- 2024
- Full Text
- View/download PDF
42. Reply.
- Author
-
Barbhaiya M, Zuily S, de Jesus G, Branch DW, and Erkan D
- Published
- 2024
- Full Text
- View/download PDF
43. A pilot study investigating severe community-acquired febrile illness through implementation of an innovative microbiological and nucleic acid amplification testing strategy in Timor-Leste (ISIN-MANAS-TL).
- Author
-
Ximenes D, de Jesus G, de Sousa AS, Soares C, Amaral LC, Oakley T, Alves L, Amaral S, Sarmento N, Guterres H, Cabral JAD, Boavida F, Yan J, Francis JR, Martins N, and Arkell P
- Abstract
Objectives: Acute febrile illness (AFI) causes significant health-seeking, morbidity, and mortality in Southeast Asia. This pilot study aimed to describe presentation, etiology, treatment, and outcomes of patients with AFI at one hospital in Timor-Leste and assessing the feasibility of conducting larger studies in this setting., Methods: Patients attending Hospital Nacional Guido Valadares with tympanic or axillary temperature ≥37.5°C in whom a blood culture was taken as part of routine clinical care were eligible. Participants were followed up daily for 10 days and again after 30 days. Whole blood was analyzed using a real-time quantitative polymerase chain reaction assay detecting dengue virus serotypes 1-4 and other arthropod-borne infections., Results: A total of 82 participants were recruited. Polymerase chain reaction testing was positive for dengue in 14 of 82 (17.1%) participants and blood culture identified a bacterial pathogen in three of 82 (3.7%) participants. Follow-up was completed by 75 of 82 (91.5%) participants. High rates of hospital admission (58 of 82, 70.7%), broad-spectrum antimicrobial treatment (34 of 82, 41.5%), and mortality (9 of 82, 11.0%) were observed., Conclusions: Patients with AFI experience poor clinical outcomes. Prospective observational and interventional studies assessing interventions, such as enhanced diagnostic testing, clinical decision support tools, or antimicrobial stewardship interventions, are required and would be feasible to conduct in this setting., Competing Interests: The authors have no competing interest to declare., (© 2024 The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
44. Deciphering the clinical significance of longitudinal antiphospholipid antibody titers.
- Author
-
Chighizola CB, Willis R, Maioli G, Sciascia S, Andreoli L, Amengual O, Radin M, Gerosa M, Atsumi T, de Jesus G, Trespidi L, Branch DW, Caporali R, Andrade D, Roubey R, Petri M, and Bertolaccini ML
- Subjects
- Humans, Lupus Erythematosus, Systemic immunology, Lupus Erythematosus, Systemic blood, Lupus Erythematosus, Systemic diagnosis, Lupus Erythematosus, Systemic drug therapy, beta 2-Glycoprotein I immunology, Thrombosis immunology, Thrombosis blood, Thrombosis etiology, Clinical Relevance, Antibodies, Antiphospholipid blood, Antibodies, Antiphospholipid immunology, Antiphospholipid Syndrome immunology, Antiphospholipid Syndrome blood, Antiphospholipid Syndrome diagnosis
- Abstract
In antiphospholipid syndrome (APS), the risk of clinical manifestations increases with higher titers of antiphospholipid antibodies (aPL). Despite the adoption of aPL titers in the classification approach to aPL-positive subjects, the value of longitudinal monitoring of those titers in the follow-up is still debated, being well studied only in systemic lupus erythematosus (SLE). The literature suggests that the rate of aPL positivity decreases during follow-up in primary APS, estimating that seroconversion occurs in between 8.9 and 59% of patients over time. Negativisation of aPL occurs more frequently in asymptomatic aPL carriers than in patients with full-blown APS as well as in subjects with single aPL positivity or low aPL antibody titers. In patients with SLE, aPL typically behave fluctuating from positive to negative and back again in the course of follow-up. The few studies assessing the longitudinal course of aPL positivity with no associated systemic connective tissue disease reported a progressive decrement of aPL titers over time, in particular of antibodies against β2 glycoprotein I (antiβ2GPI) and cardiolipin (aCL) of IgG isotype. After a thrombotic event, aPL titers tend to decrease, as emerged from cohorts of both primary and secondary APS. Hydroxychloroquine has been identified as the most effective pharmacological agent to reduce aPL titers, with multiple studies demonstrating a parallel reduction in thrombosis rate. This review addresses available evidence on the significance of aPL titer fluctuation from clinical, therapeutic and pathogenic perspectives., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
45. Feasibility and performance of a combined extracorporeal assisted cardiac resuscitation and an organ donation program after uncontrolled cardiocirculatory death (Maastricht II).
- Author
-
Nobre de Jesus G, Neves I, Gouveia J, and Ribeiro J
- Subjects
- Humans, Male, Middle Aged, Female, Feasibility Studies, Retrospective Studies, Cardiopulmonary Resuscitation methods, Out-of-Hospital Cardiac Arrest therapy, Extracorporeal Membrane Oxygenation methods, Tissue and Organ Procurement
- Abstract
Introduction: Approximately 500.000 people in Europe sustain cardiac arrest (CA) every year, being myocardial infarction the main etiology. Interest has been raised in a new approach to refractory cardiac arrest (rCA) using extra-corporeal oxygenation (ECMO). In settings where it can be rapidly implemented, ECMO assisted resuscitation (ECPR) may be considered. Additionally, donation after circulatory death, which seeks to obtain solid organs donation from patients suffering rCA, has increased its role effectively increasing the pool of donors. Combined programs with integration of ECPR and uncontrolled donation after circulatory determination of death (uDCDD) are worldwide limited and experience integrating these two techniques is lacking., Methods: We report a 24 months experience of ECPR and uDCDD kidney transplantation based on a management protocol in a university teaching hospital in the urban area of Lisbon., Results: Over a period of 24 months, 58 patients were admitted to our ICU with rCA, 6 (10%) in the ECPR program and 52 (90%) in the uDCDD. Seventy-eight percent of patients were male, with an average age of 49 year-old. CA was witnessed in 83% of cases and initial rhythm was ventricular fibrillation in 20 cases (35%). 13 (25%) patients were effective organ donors. Refusal for effective donation was mainly due to prior comorbidities., Discussion: The development of an integrated program for ECPR and uDCDD is feasible and requires a well-established and efficient activation program. In an era of significant organ shortage, it provides a viable option for increasing the organ donation pool, with promising results., Competing Interests: Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
- Published
- 2024
- Full Text
- View/download PDF
46. The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria.
- Author
-
Barbhaiya M, Zuily S, Naden R, Hendry A, Manneville F, Amigo MC, Amoura Z, Andrade D, Andreoli L, Artim-Esen B, Atsumi T, Avcin T, Belmont HM, Bertolaccini ML, Branch DW, Carvalheiras G, Casini A, Cervera R, Cohen H, Costedoat-Chalumeau N, Crowther M, de Jesus G, Delluc A, Desai S, De Sancho M, Devreese KM, Diz-Kucukkaya R, Duarte-Garcia A, Frances C, Garcia D, Gris JC, Jordan N, Leaf RK, Kello N, Knight JS, Laskin C, Lee AI, Legault K, Levine SR, Levy RA, Limper M, Lockshin MD, Mayer-Pickel K, Musial J, Meroni PL, Orsolini G, Ortel TL, Pengo V, Petri M, Pons-Estel G, Gomez-Puerta JA, Raimboug Q, Roubey R, Sanna G, Seshan SV, Sciascia S, Tektonidou MG, Tincani A, Wahl D, Willis R, Yelnik C, Zuily C, Guillemin F, Costenbader K, and Erkan D
- Subjects
- Female, Pregnancy, Humans, United States, beta 2-Glycoprotein I, Autoantibodies, Immunoglobulin G, Immunoglobulin M, Antiphospholipid Syndrome, Rheumatology
- Abstract
Objective: To develop new antiphospholipid syndrome (APS) classification criteria with high specificity for use in observational studies and trials, jointly supported by the American College of Rheumatology (ACR) and EULAR., Methods: This international multidisciplinary initiative included 4 phases: 1) Phase I, criteria generation by surveys and literature review; 2) Phase II, criteria reduction by modified Delphi and nominal group technique exercises; 3) Phase III, criteria definition, further reduction with the guidance of real-world patient scenarios, and weighting via consensus-based multicriteria decision analysis, and threshold identification; and 4) Phase IV, validation using independent adjudicators' consensus as the gold standard., Results: The 2023 ACR/EULAR APS classification criteria include an entry criterion of at least one positive antiphospholipid antibody (aPL) test within 3 years of identification of an aPL-associated clinical criterion, followed by additive weighted criteria (score range 1-7 points each) clustered into 6 clinical domains (macrovascular venous thromboembolism, macrovascular arterial thrombosis, microvascular, obstetric, cardiac valve, and hematologic) and 2 laboratory domains (lupus anticoagulant functional coagulation assays, and solid-phase enzyme-linked immunosorbent assays for IgG/IgM anticardiolipin and/or IgG/IgM anti-β
2 -glycoprotein I antibodies). Patients accumulating at least 3 points each from the clinical and laboratory domains are classified as having APS. In the validation cohort, the new APS criteria versus the 2006 revised Sapporo classification criteria had a specificity of 99% versus 86%, and a sensitivity of 84% versus 99%., Conclusion: These new ACR/EULAR APS classification criteria were developed using rigorous methodology with multidisciplinary international input. Hierarchically clustered, weighted, and risk-stratified criteria reflect the current thinking about APS, providing high specificity and a strong foundation for future APS research., (© 2023 American College of Rheumatology.)- Published
- 2023
- Full Text
- View/download PDF
47. Nutrient uptake in supplemented substrate by oyster mushroom.
- Author
-
Lucas de Jesus G, José Lavoranti O, Schafer G, Dias de Oliveira G, Scheffer de Andrade Silva R, and Lorena Cuquel F
- Subjects
- Triticum, Nutrients, Dietary Supplements, Pleurotus, Agaricales
- Abstract
Spent mushroom substrate (SMS) is a promising alternative for supplementing oyster mushroom substrate, replacing conventional cereal bran. Therefore, the objective was to evaluate the production of Pleurotus ostreatus supplemented with Lentinula edodes' SMS, through the nutritional analysis of the substrate. Wheat straw was used as substrate and supplemented with rice bran (RB) or SMS in 0%, 7%,15% and 30%. Ca, K, Mg, Mn, Zn, Cu and Fe contents of the cultivation substrates (before and after harvest) were determined through atomic absorption spectrophotometry. Mycelial growth (cm²/day), mycelial time colonization (days), number of clusters, number of pileus, average clusters weight (g), pileus lenght (cm) and width (cm), productivity (1st, 2nd and 3rd flush) (%), biological efficiency (%) of mushrooms were evaluated. Results indicated mycelial growth was higher (0.87 cm²/day compared to the Control) when the substrate was supplemented regardless of the source. The proportions of 15% of SMS achieved the highest biological efficiency (107% - 15% SMS versus 66% - Control). The only nutrients that showed differences in absorption were Ca, K and Mn, in which substrates supplemented with SMS had greater absorption of Ca (5.37 g.kg
- 1 versus 1.94 g.kg- 1 in Control) while substrates supplemented with RB absorbed more K (6.56 g.kg- 1 versus 3.74 g.kg- 1 in Control). The mineral composition of the substrate has a direct impact on the growth and yield of P. ostreatus, highlighting the potential of SMS as a alternative to traditional bran supplementation., (© 2023. The Author(s), under exclusive licence to Springer Nature B.V.)- Published
- 2023
- Full Text
- View/download PDF
48. The Effects of Chitosan on the Healing Process of Oral Mucosa: An Observational Cohort Feasibility Split-Mouth Study.
- Author
-
de Jesus G, Marques L, Vale N, and Mendes RA
- Abstract
The healing process is a dynamic process accompanied by some classical symptoms of inflammation such as redness, swelling, pain, and loss of function. Chitosan is a natural polymer with properties that contribute to tissue healing, with properties that could be applied in periodontal therapy, such as the wound healing of oral mucosa. This experimental split-mouth study aims to assess the possibilities of chitosan influencing the healing process of oral mucosa in eight patients, where the studied group was subjected to two oral surgeries: one with chitosan hydrogel into the socket and other without the biomaterial. A semi-quantitative analysis of the data was performed. Some classic signs of inflammation in a short period of time were observed where chitosan acted, compared to the control. An absence of bleeding was observed in the chitosan cases. According to the literature, chitosan recruits and activates neutrophils and macrophages and stimulates angiogenesis. Hemostatic and antimicrobial activity of chitosan also play an important role in wound healing. Chitosan seems to improve the postoperative quality of patients, allowing rapid wound healing with less complications.
- Published
- 2023
- Full Text
- View/download PDF
49. Exercise Capacity and Biomarkers Among Children and Adolescents With Sickle Cell Disease.
- Author
-
Silva LBPD, Mercês de Jesus G, Bessa Junior J, Silva VAPD, Mattos IG, Jenerette CM, and Carvalho ESS
- Subjects
- Male, Humans, Child, Adolescent, Child, Preschool, Female, Cross-Sectional Studies, Interleukin-6, Walking physiology, Biomarkers, Exercise Test, Exercise Tolerance physiology, Anemia, Sickle Cell
- Abstract
Background: Sickle cell disease is the most common genetic hemoglobinopathy globally and systemically affects body functioning, decreasing exercise capacity., Objective: To assess exercise capacity through the 6-minute walk test (6MWT) and biomarkers in children and adolescents with sickle cell disease., Materials and Methods: Cross-sectional study involving 20 children and adolescents from Brazil. Demographic and socioeconomic data were obtained. Baseline measurements included biomarkers (red blood cells, hemoglobin, hematocrit, white blood cells, platelets, reticulocytes, lactate dehydrogenase, creatine phosphokinase, C-reactive protein, interleukin 6, and fetal hemoglobin). The following data were obtained before, during, and after the 6MWT: heart rate, blood pressure, and peripheral oxygen saturation., Results: Eighteen children and adolescents ages 5-14 years old were analyzed, 61.1% boys, 100% black or brown, and 61.1% in primary education, with low household income. The average distance walked in 6MWT was 463.8 (137.7) m, significantly less than the predicted value (P < .001). The distance of 6MWT was associated positively with age (P = .042) and inversely with reticulocyte count (P = .42) and interleukin 6 (P = .00). Age modified the effect of interleukin 6 in younger children (P = .038)., Conclusion: Our findings suggest increased baseline levels of biomarkers of hemolysis and inflammation impact on 6MWT performance.
- Published
- 2022
- Full Text
- View/download PDF
50. Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria.
- Author
-
Barbhaiya M, Zuily S, Ahmadzadeh Y, Amigo MC, Avcin T, Bertolaccini ML, Branch DW, de Jesus G, Devreese KMJ, Frances C, Garcia D, Guillemin F, Levine SR, Levy RA, Lockshin MD, Ortel TL, Seshan SV, Tektonidou M, Wahl D, Willis R, Naden R, Costenbader K, and Erkan D
- Subjects
- Antiphospholipid Syndrome classification, Antiphospholipid Syndrome immunology, Consensus, Delphi Technique, Humans, Predictive Value of Tests, Severity of Illness Index, Antiphospholipid Syndrome diagnosis, Rheumatology standards
- Abstract
Objective: An international multidisciplinary initiative, jointly supported by the American College of Rheumatology and European Alliance of Associations for Rheumatology, is underway to develop new rigorous classification criteria to identify patients with high likelihood of antiphospholipid syndrome (APS) for research purposes. The present study was undertaken to apply an evidence- and consensus-based approach to identify candidate criteria and develop a hierarchical organization of criteria within domains., Methods: During phase I, the APS classification criteria steering committee used systematic literature reviews and surveys of international APS physician scientists to generate a comprehensive list of items related to APS. In phase II, we reviewed the literature, administered surveys, formed domain subcommittees, and used Delphi exercises and nominal group technique to reduce potential APS candidate criteria. Candidate criteria were hierarchically organized into clinical and laboratory domains., Results: Phase I generated 152 candidate criteria, expanded to 261 items with the addition of subgroups and candidate criteria with potential negative weights. Using iterative item reduction techniques in phase II, we initially reduced these items to 64 potential candidate criteria organized into 10 clinical and laboratory domains. Subsequent item reduction methods resulted in 27 candidate criteria, hierarchically organized into 6 additive domains (laboratory, macrovascular, microvascular, obstetric, cardiac, and hematologic) for APS classification., Conclusion: Using data- and consensus-driven methodology, we identified 27 APS candidate criteria in 6 clinical or laboratory domains. In the next phase, the proposed candidate criteria will be used for real-world case collection and further refined, organized, and weighted to determine an aggregate score and threshold for APS classification., (© 2020, American College of Rheumatology.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.